9.23

1.32% 0.12

After Hours: 9.25 0.02 +0.22%

Neogenomics Inc (NEO)

Overview News Price History Option Chain Financials Why NEO Down? Discussions Forecast Stock Split

Neogenomics Inc stock is traded at $9.23, with a volume of 778.75K. It is up +1.32% in the last 24 hours and up +12.84% over the past month. NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Previous Close:

$9.11

Open:

$9.11

24h Volume:

778.75K

Relative Volume:

0.40

Market Cap:

$1.20B

Revenue:

$745.97M

Net Income/Loss:

$-99.21M

P/E Ratio:

-11.94

EPS:

-0.7729

Net Cash Flow:

$-5.09M

1W Performance:

+12.01%

1M Performance:

+12.84%

6M Performance:

-19.60%

1Y Performance:

+26.79%

1-Day Range:

$9.07

$9.36

1-Week Range:

$8.20

$9.36

52-Week Range:

$4.72

$13.74

Neogenomics Inc Stock (NEO) Company Profile

Name

Neogenomics Inc

Sector

Healthcare (1108)

Industry

Diagnostics & Research (52)

Phone

(239) 768-0600

Address

9490 NEOGENOMICS WAY, FORT MYERS, FL

Employee

2,500

Twitter

@NeoGenomics

Next Earnings Date

2026-04-28

Latest SEC Filings

NEO's Discussions on Twitter

Compare NEO vs TMO, DHR, IDXX, WAT, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NEO Neogenomics Inc	9.23	1.19B	745.97M	-99.21M	-5.09M	-0.7729
TMO Thermo Fisher Scientific Inc	448.28	167.00B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	172.00	122.68B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	559.37	43.63B	4.45B	1.10B	1.06B	13.59
WAT Waters Corp	342.37	33.48B	3.77B	449.25M	240.68M	7.8556
A Agilent Technologies Inc	114.96	32.44B	7.07B	1.29B	993.00M	4.5355

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-25	Downgrade	BTIG Research	Buy → Neutral
Jul-29-25	Downgrade	William Blair	Outperform → Mkt Perform
May-15-25	Initiated	Guggenheim	Neutral
Apr-30-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jan-13-25	Downgrade	The Benchmark Company	Buy → Hold
Dec-10-24	Initiated	Jefferies	Buy
May-01-24	Resumed	Craig Hallum	Buy
Dec-29-23	Reiterated	BTIG Research	Buy
Aug-21-23	Upgrade	Stephens	Equal-Weight → Overweight
May-16-23	Downgrade	Raymond James	Outperform → Mkt Perform
May-09-23	Upgrade	BTIG Research	Neutral → Buy
Feb-24-23	Upgrade	The Benchmark Company	Hold → Buy
Feb-01-23	Upgrade	Needham	Hold → Buy
Aug-26-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-22-22	Downgrade	Needham	Buy → Hold
Jun-03-22	Initiated	Piper Sandler	Overweight
Mar-29-22	Downgrade	BofA Securities	Buy → Neutral
Mar-29-22	Downgrade	Stephens	Overweight → Equal-Weight
Jan-18-22	Resumed	Stephens	Overweight
Dec-16-21	Initiated	Cowen	Outperform
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-03-21	Initiated	Goldman	Buy
Feb-25-21	Resumed	Needham	Buy
Feb-25-21	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-28-21	Initiated	Truist	Buy
Dec-11-20	Resumed	BTIG Research	Buy
Oct-28-20	Reiterated	Needham	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Aug-28-20	Initiated	Guggenheim	Buy
Jul-29-20	Reiterated	Needham	Buy
Jun-25-20	Initiated	BofA/Merrill	Buy
Apr-21-20	Resumed	Stephens	Overweight
Mar-02-20	Resumed	Craig Hallum	Buy
Feb-28-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Jan-23-20	Downgrade	First Analysis Sec	Strong Buy → Outperform
Oct-30-19	Reiterated	Needham	Buy
May-01-19	Reiterated	Needham	Buy
Mar-29-19	Reiterated	Needham	Buy
Jan-03-19	Initiated	Needham	Buy
Oct-24-18	Upgrade	First Analysis Sec	Outperform → Strong Buy
Aug-21-18	Initiated	Leerink Partners	Outperform
May-02-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Sep-11-17	Downgrade	BTIG Research	Buy → Neutral
Aug-24-17	Initiated	Gabelli & Co	Buy
Dec-15-16	Initiated	Cantor Fitzgerald	Overweight

View All

Neogenomics Inc Stock (NEO) Latest News

May 25, 2026

(NEO) Risk Channels and Responsive Allocation - Stock Traders Daily

May 25, 2026

May 22, 2026

A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $11 to $25 - Moomoo

May 22, 2026

Shareholders approve NeoGenomics (NASDAQ: NEO) equity plan amendment and board slate - Stock Titan

May 22, 2026

May 20, 2026

NeoGenomics Earnings Call Highlights NGS-Driven Momentum - TipRanks

May 20, 2026

May 19, 2026

NeoGenomics stock (US64049M2098): Q1 update keeps focus on cancer testing demand - AD HOC NEWS

May 19, 2026

May 17, 2026

NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know - Yahoo Finance

May 17, 2026

May 15, 2026

NEOGENOMICS (NEO) 13G/A: Greenhouse reports 9,215,903 shares (7.1%) - Stock Titan

May 15, 2026

NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval - MSN

May 15, 2026

Oncology diagnostics group NeoGenomics meets investors at May, June conferences - Stock Titan

May 15, 2026

Millennium group reports 2.22M NEO shares (1.7%) — Joint filing (NEO) - Stock Titan

May 13, 2026

NeoGenomics (NEO) EVP adds shares via RSU vesting while covering taxes - Stock Titan

May 13, 2026

NeoGenomics (NEO) COO exercises RSUs, withholds shares for taxes and holds 164,032 shares - Stock Titan

May 13, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO? - Sahm

May 11, 2026

May 09, 2026

NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

May 09, 2026

May 08, 2026